-
Something wrong with this record ?
Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase
J. Gregor, K. Radilová, J. Brynda, J. Fanfrlík, J. Konvalinka, M. Kožíšek
Language English Country Switzerland
Document type Journal Article
Grant support
CZ.02.1.01/0.0/0.0/16_019/0000729
European Regional Development Fund; OP RDE; Project: "Chemical biology for drugging undruggable targets (ChemBioDrug)
NLK
Directory of Open Access Journals
from 1997
Free Medical Journals
from 1997
PubMed Central
from 2001
Europe PubMed Central
from 2001
ProQuest Central
from 1997-01-01
Open Access Digital Library
from 1997-01-01
Medline Complete (EBSCOhost)
from 2009-03-01
Health & Medicine (ProQuest)
from 1997-01-01
- MeSH
- Crystallography, X-Ray MeSH
- Quantum Theory MeSH
- Models, Molecular MeSH
- Mutation genetics MeSH
- Mutant Proteins metabolism MeSH
- Protein Subunits antagonists & inhibitors chemistry metabolism MeSH
- Protein Domains MeSH
- Pyridines chemistry pharmacology MeSH
- Pyrimidines chemistry pharmacology MeSH
- Pyrroles chemistry pharmacology MeSH
- RNA-Dependent RNA Polymerase antagonists & inhibitors chemistry metabolism MeSH
- Thermodynamics MeSH
- Drug Resistance, Viral drug effects MeSH
- Viral Proteins antagonists & inhibitors chemistry metabolism MeSH
- Influenza A virus drug effects enzymology MeSH
- Publication type
- Journal Article MeSH
Influenza A virus (IAV) encodes a polymerase composed of three subunits: PA, with endonuclease activity, PB1 with polymerase activity and PB2 with host RNA five-prime cap binding site. Their cooperation and stepwise activation include a process called cap-snatching, which is a crucial step in the IAV life cycle. Reproduction of IAV can be blocked by disrupting the interaction between the PB2 domain and the five-prime cap. An inhibitor of this interaction called pimodivir (VX-787) recently entered the third phase of clinical trial; however, several mutations in PB2 that cause resistance to pimodivir were observed. First major mutation, F404Y, causing resistance was identified during preclinical testing, next the mutation M431I was identified in patients during the second phase of clinical trials. The mutation H357N was identified during testing of IAV strains at Centers for Disease Control and Prevention. We set out to provide a structural and thermodynamic analysis of the interactions between cap-binding domain of PB2 wild-type and PB2 variants bearing these mutations and pimodivir. Here we present four crystal structures of PB2-WT, PB2-F404Y, PB2-M431I and PB2-H357N in complex with pimodivir. We have thermodynamically analysed all PB2 variants and proposed the effect of these mutations on thermodynamic parameters of these interactions and pimodivir resistance development. These data will contribute to understanding the effect of these missense mutations to the resistance development and help to design next generation inhibitors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21019249
- 003
- CZ-PrNML
- 005
- 20210830100828.0
- 007
- ta
- 008
- 210728s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/molecules26041007 $2 doi
- 035 __
- $a (PubMed)33673017
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Gregor, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic $u First Faculty of Medicine, Charles University, Kateřinská 1660/32, 12108 Prague 2, Czech Republic
- 245 10
- $a Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase / $c J. Gregor, K. Radilová, J. Brynda, J. Fanfrlík, J. Konvalinka, M. Kožíšek
- 520 9_
- $a Influenza A virus (IAV) encodes a polymerase composed of three subunits: PA, with endonuclease activity, PB1 with polymerase activity and PB2 with host RNA five-prime cap binding site. Their cooperation and stepwise activation include a process called cap-snatching, which is a crucial step in the IAV life cycle. Reproduction of IAV can be blocked by disrupting the interaction between the PB2 domain and the five-prime cap. An inhibitor of this interaction called pimodivir (VX-787) recently entered the third phase of clinical trial; however, several mutations in PB2 that cause resistance to pimodivir were observed. First major mutation, F404Y, causing resistance was identified during preclinical testing, next the mutation M431I was identified in patients during the second phase of clinical trials. The mutation H357N was identified during testing of IAV strains at Centers for Disease Control and Prevention. We set out to provide a structural and thermodynamic analysis of the interactions between cap-binding domain of PB2 wild-type and PB2 variants bearing these mutations and pimodivir. Here we present four crystal structures of PB2-WT, PB2-F404Y, PB2-M431I and PB2-H357N in complex with pimodivir. We have thermodynamically analysed all PB2 variants and proposed the effect of these mutations on thermodynamic parameters of these interactions and pimodivir resistance development. These data will contribute to understanding the effect of these missense mutations to the resistance development and help to design next generation inhibitors.
- 650 _2
- $a krystalografie rentgenová $7 D018360
- 650 _2
- $a virová léková rezistence $x účinky léků $7 D024882
- 650 _2
- $a virus chřipky A $x účinky léků $x enzymologie $7 D009980
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a mutantní proteiny $x metabolismus $7 D050505
- 650 _2
- $a mutace $x genetika $7 D009154
- 650 _2
- $a proteinové domény $7 D000072417
- 650 _2
- $a podjednotky proteinů $x antagonisté a inhibitory $x chemie $x metabolismus $7 D021122
- 650 _2
- $a pyridiny $x chemie $x farmakologie $7 D011725
- 650 _2
- $a pyrimidiny $x chemie $x farmakologie $7 D011743
- 650 _2
- $a pyrroly $x chemie $x farmakologie $7 D011758
- 650 _2
- $a kvantová teorie $7 D011789
- 650 _2
- $a RNA-dependentní RNA-polymerasa $x antagonisté a inhibitory $x chemie $x metabolismus $7 D012324
- 650 _2
- $a termodynamika $7 D013816
- 650 _2
- $a virové proteiny $x antagonisté a inhibitory $x chemie $x metabolismus $7 D014764
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Radilová, Kateřina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic $u First Faculty of Medicine, Charles University, Kateřinská 1660/32, 12108 Prague 2, Czech Republic
- 700 1_
- $a Brynda, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic
- 700 1_
- $a Fanfrlík, Jindřich $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12800 Prague 2, Czech Republic
- 700 1_
- $a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic
- 773 0_
- $w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 26, č. 4 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33673017 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210728 $b ABA008
- 991 __
- $a 20210830100828 $b ABA008
- 999 __
- $a ok $b bmc $g 1690143 $s 1139695
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 26 $c 4 $e 20210214 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000729 $p European Regional Development Fund; OP RDE; Project: "Chemical biology for drugging undruggable targets (ChemBioDrug)
- LZP __
- $a Pubmed-20210728